ArticleJHLT open2025
Cumulative weight-based rabbit antithymocyte globulin dosing for induction in heart transplantation: Impact on outcomes.
Article in JHLT open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Optimal dose of rabbit antithymocyte globulin (rATG) for heart transplantation (HTx) induction remains uncertain. We conducted a retrospective analysis to assess the effect of cumulative rATG weight-based dosing in HTx induction. Methods: We retrospectively analyzed a total of 340 primary HTx patients (1983-2018) receiving a fixed rATG dose (125 mg daily for 3 days). Patients were retrospectively categorized based on cumulative rATG exposition: group A (<4.5 mg/kg), group B (4.5-7.5 mg/kg), and group C (>7.5 mg/kg). The primary composite outcome (death, acute rejection, and infection) and its components were evaluated at 24 months using absolute incidence, Kaplan-Meier survival curves, and Cox modeling. Results: Group A had a non-significant lower incidence of the primary composite end-point (A: 76.8%, B: 83.7%, C: 96.2%; Conclusions: At 24 months post-HTx, our findings suggest that a cumulative rATG dosing of 4.5 to 7.5 mg/kg offers the best balance of AR, mortality, and infection, mainly by reducing the risk of infections and to a lesser degree mortality, without increasing AR. A cumulative dose of <4.5 mg/kg offers the lowest risk of infection, with 4.5 mg/kg likely representing the intersection dose.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.